PXD021604 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | Cellular States Dictate Adaptive Signaling Responses to KRASG12C Inhibition: Tyrosine Phosphorylation |
Description | Covalent inhibitors of KRASG12C (KRASi) hold considerable progress for tumors driven by this oncogene yet early studies suggest rapid mechanisms of adaptive resistance that appear cell type dependent. To address these challenges, we performed mass spsectrometry baesd phosphoproteomics analysis in KRASG12C cell lines after short term treatment with ARS-1620 and compared phosphoproteomes of KRASG12C cells to understand signaling diversity. Our analysis suggests individual KRASG12C cells responds uniquely to perturbation of KRASG12C. Cell line models can be categorized in epithelial or mesenchymal subtypes and a similar pattern was observed in KRASG12C human lung cancer tumor tissues. ERBB2/3 signaling compensate for repressed ERK signaling following ARS-1620 treatment in epithelial cell type, and this subtype was also more responsive to inhibition of SHP2, IGFR, and SOS1. Conversely, FGFR signaling drives resistance to KRASi in mesenchymal cells in part via mTOR signaling. These studies suggest transcriptional subtypes of KRASG12C dictate responsiveness to specific combinations. |
HostingRepository | PRIDE |
AnnounceDate | 2021-02-16 |
AnnouncementXML | Submission_2021-02-16_06:07:18.xml |
DigitalObjectIdentifier | https://dx.doi.org/10.6019/PXD021604 |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Supported dataset by repository |
PrimarySubmitter | John Koomen |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | phosphorylated residue; monohydroxylated residue; iodoacetamide derivatized residue |
Instrument | Q Exactive |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2020-09-22 01:59:04 | ID requested | |
1 | 2021-02-15 08:08:42 | announced | |
⏵ 2 | 2021-02-16 06:07:18 | announced | 2021-02-16: Updated project metadata. |
Publication List
Dataset with its publication pending |
Keyword List
submitter keyword: Lung Cancer, KRAS, phosphoproteomics, mass spectrometry, receptor tyrosine kinases (RTK), targeted therapy, drug resistance, signal transduction |
Contact List
Eric Haura, MD |
contact affiliation | Thoracic Oncology |
contact email | eric.haura@moffitt.org |
lab head | |
John Koomen |
contact affiliation | Moffitt Cancer Center |
contact email | john.koomen@moffitt.org |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/02/PXD021604 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD021604
- Label: PRIDE project
- Name: Cellular States Dictate Adaptive Signaling Responses to KRASG12C Inhibition: Tyrosine Phosphorylation